Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Good to see people more or less getting along with a mature conversation on timelines, also good to see the continued good points put across by all of your familiar names. The recent boom in cases along with a concerning trendline for hospital admissions (especially in the NE) despite the "vaccination wall" is unfortunate, and only strengthens the need for a combination with effective therapeutics. We always knew this and it's why we don't have issues waiting for the inevitable solid results.
Well said everyone. If you wish to look at the SP frequently then do so, but we're waiting for incoming news so there's no reason at all to be discouraged (been here before many times). If gluing your eyes to the SP movement and inhaling any negativity isn't doing much for you, take a break.
Well said, we've come a long way and there is no doubt in my mind we're in for a treat!
Don't worry, all us LTH are here but patiently waiting with solid faith.
If there was a way to pin posts to the top of the board, this would be one of them. People seem to forget these important points - well said.
Great find, Jez. I agree with others here that something big behind the scenes is pushing this price up, and it's clear from both a medical and political standpoint that Synairgen are about to take the spotlight very soon.
We always knew it was going this way, and to repeat RM's statement recently: "Our phase 2 data is the strongest in the world for covid" - since then, the team over at Synairgen have done nothing but constantly learn which helps them target the drug even better. So, with this in mind, repeating his statement right after that: "If we get the same in phase three it will be transformational for Synairgen", couple this with imminent Activ2 news and it's clear as day why we're here.
A heartfelt salute to everyone here who held and continue to post invaluable information like this :).
Thanks for sharing Oak, this is incredible - these hires are pointing towards massive rewards for investors. Very interesting seeing the discussions surrounding takeover vs licensing also, of course the advantage of a takeover would be the clear cut decision made for you, and the quickest route, at the expense of potentially lower value.
This thread has brought back a lot of healthy discussion which is great to see again, here's hoping that we can somewhat stay like this until news! Personally, this and the CFO hire strengthens my conviction here - as if it needed strengthening anymore anyway!
All great points, Novice. These are the reasons why the genuine investors here are staying put, the value that the drug presents cannot be ignored. The idea that Covid has somehow been completely eliminated here is entirely incorrect as we saw from the tail end of the last lockdown, and an extreme number of people continue to be affected globally.
You cannot vaccinate someone when they already have the virus, and are either deteriorating or suffering from severe symptoms - there must be an answer from multiple angles. Extending from this, the optimism for vaccine efficacy is unfortunately unfounded for the newer variants - therefore, the protocol to keep people from severe deterioration would firstly require vaccination of the population with both doses and future boosters, and if this fails (whether that's due to lack of efficacy against other strains, or a population not being vaccinated), a treatment would be required to keep people out of hospitals. Unfortunately, the rate at which Covid mutates is staggering, and that hasn't even been with a global removal of restrictions.
A great result from P2, coupled with the Home Trial data, reinforces that P3 is going to deliver further incredible results. The emotional shifts up and down along with the SP chart between P2 and P3 do not matter.
Good points. The data was good and supports P3 greatly, science hasn't changed, I wish I could pick up some more at this price. Seems like others are doing that already though.
Some good points made here. The assumption that the vaccines maintain their efficacy across all of the variants is incorrect, there is no data to suggest this (which one would you even be talking about? There are different data for each of them), and every new variant would require the same rugged testing.
With all of this in mind, there hasn't been enough time to properly measure this efficacy. Additionally, the fact that we've observed this many variants already throughout the cycles of easing and enforcing of restrictions suggests that this would be exacerbated by prolonged and wider lifting of restrictions, not even factoring in the potential of easing said restrictions globally.
The RNS was good and the data is positive, along with the science not changing. If PIs are actually selling based on misinterpreting this RNS, then they have not understood the gravity of what this means for this as a treatment. It comes back to what Ghia just said:
"This targeting of the use and clear clinical benefit in that subset will IMO justify a high asking price."
Combining this with P2 means everything, which is that all signs point to P3 delivering outstanding results - this always being the end goal, and now it's been de-risked further.
Let the dust settle and relax.
Agreed, the narrow minded vision won't get you anywhere. The data so far gives us everything we need to be confident that those who progress to breathlessness, and those in the hospital setting, will benefit greatly from the drug. There were both mild (non-breathless and below) and slightly worse (breathless) patients, and the data showed that the first group wouldn't have required treatment anyway - and of course, this means that patients with more progressed symptoms respond very well to the drug. This gives us an overwhelming amount of confidence for P3.
RM: "Although not many people became ill (in the home trial), the whole data set has given us a very clear steer on who should be treated with this drug, and overall we're very pleased, it increases our confidence that the Phase 3 trial is going to readout positively in the second half of this year."
We're set very positively now for what was always our goal: P3 readout. Enjoy the day everyone, and try not to get swept up into the doom and gloom, I understand that some people found the presentation boring because it contained data and science, but "downbeat" was definitely not the tone.
Good summary, nessab. I agree, the fact that this works better from breathlessness and beyond is everything we need to go into P3, and if breathlessness occurs in the home setting, then SNG001 can treat this; anything under this level of severity and the patients would have recovered themselves anyway. People seem to have forgotten that key point, that this was a small piece of the puzzle which proved to be effective.
"The phase 3 has just been de-risked by todays information with us now knowing that the population chosen is THE best population for the drug to work". I agree, I think the reaction is probably due to a long wait without news, and then the expectation for the lid to be totally blown off; Even with the huge upside that this stops symptom progression in the home setting and the value of this for potential buyers, this dataset supports P3 far more than some people here are currently taking into consideration.
Jediknight, MrCrumpet, and Mikep - These are good points, the data shows that SNG001 is safe in the home setting, and improves breathlessness (keeping people out of hospitals). I agree and would say to worried investors to not worry about the drop, as it'll recover once the dust settles. The goal was always P3, and in times like this, it's best to focus on the drug and the cold hard facts which are that SNG001 is safe and effective.
I know people are worried about the SP, but calm down - the science didn't change.
Agreed. Safety and improvement in those with breathlessness sets a solid foundation, stack this with P3 and we have a drug that can be used in both settings. Perhaps too much expectation for a small Home Trial, but either way definitely an overreaction.
Speaking of treatments Scinv, you might need a one for that fourth degree burn you just received from Ghia.
I'm all for reading good counter points, or valid reasons that are raised which may affect the investment, but the things I'm reading don't add up to me logically. For example, you said you saw RM downplay the Home Trial results, was this in Toy Story 1, 2, 3, 4, or 5? I might have missed it! I'm going to assume that you've been a bit absent minded, and referred to the interview recorded at the beginning of March. If this is the case, and you're referring to the reply he gave to someone else where he simply gave his thoughts about the way the drug works, then yes you would be incorrect because that isn't what happened.
While I doubt that the actual investors here are concerned about reading these kinds of posts, if anyone is concerned for whatever reason about the other treatments, please look into them the same way as you have done for SNG. This should put your mind at ease, given how far along the process SNG are. And finally, if you want to play hypotheticals about another treatment being selected, this still does not change the fact that multiple treatments can be used; as it stands, no other treatments are as far along, with as compelling data - and don't forget, SNG's target is global, not just the UK.
Thank you to everyone putting their thoughts forward, a lot of people here have spent time putting down well reasoned arguments and presenting the facts (for the billionth time).
Fantastic insight, SeaBoy.
One thing that goes overlooked far too often is the domino effect on the rest of the global healthcare system components. Yes the hospitals are completely overloaded, but that's only the beginning of the story when it comes to the future repercussions that will keep patients overly reliant on healthcare systems.
It's easy to forget the value of something that can take these loads away from all of the different healthcare components, which is priceless.
Great find, feels like we're picking up traction. The science has always held up, and I have no doubt we'll keep seeing future papers supporting it.
Phil I reckon you'll jump a few hundred spots now because you said all of those in one sentence! Don't forget 'rocket launch to the moon', lol.